AlphaMed Press Launches New Journal: STEM CELLS TRANSLATIONAL MEDICINE

Share Article

AlphaMed Press, publisher of STEM CELLS, the oldest peer-reviewed journal solely dedicated to the field, announces the launch of its newest internationally peer-reviewed journal, STEM CELLS TRANSLATIONAL MEDICINE. STEM CELLS TRANSLATIONAL MEDICINE answers an acknowledged need within the research and clinical communities for comprehensive coverage of stem cell science, stem cell-based regenerative medicine and tissue engineering, stem cell-based predictive toxicology, and cancer stem cell investigation. The inaugural issue’s articles are now available at http://stemcellstm.alphamedpress.org/.

SCTM
“STEM CELLS TRANSLATIONAL MEDICINE will further the growth and development of this fast-moving field.

AlphaMed Press, publisher of STEM CELLS, the oldest peer-reviewed journal solely dedicated to the field, announces the launch of its newest internationally peer-reviewed journal, STEM CELLS TRANSLATIONAL MEDICINE. STEM CELLS TRANSLATIONAL MEDICINE answers an acknowledged need within the research and clinical communities for comprehensive coverage of stem cell science, stem cell-based regenerative medicine and tissue engineering, stem cell-based predictive toxicology, and cancer stem cell investigation. The inaugural issue’s articles are now available at http://stemcellstm.alphamedpress.org/.

“STEM CELLS TRANSLATIONAL MEDICINE will further the growth and development of this fast-moving field,” said Anthony Atala, MD, Editor. “With its sister journal STEM CELLS, it will play an important role in the effective translation of science endeavor to clinical applications that can benefit patients.”

Published monthly, this new publication bridges stem cell research with clinical trials and applications, publishing high-impact, peer-reviewed articles, case studies, commentaries, and positive as well as negative clinical trials.

The scope of content in STEM CELLS TRANSLATIONAL MEDICINE will encompass Embryonic Stem Cells/Induced Pluripotent Stem (iPS) Cells; Fetal and Neonatal Stem Cells; Tissue-Specific Progenitor and Stem Cells; Cell-Based Drug Development, Screening and Toxicology; Enabling Technologies for Cell-Based Clinical Translation; Cancer Stem Cells; Standards, Policies and Regulations for Cell-Based Therapies; Protocols and Manufacturing for Cell-Based Therapies; and Tissue Engineering and Regenerative Medicine.

The potential of stem cell therapies and regenerative medicine is both provocative and unique. The inaugural issue of STEM CELLS TRANSLATIONAL MEDICINE presents compelling cell implantation technologies with novel tissue/organ repair and regeneration protocols, including a novel research platform with proof of concept studies in degenerative disease models. Under the editorial leadership of esteemed scientist-clinician Dr. Atala, STEM CELLS TRANSLATIONAL MEDICINE aims to speed expertly executed translations of emerging lab discoveries into clinical trials and ultimately bedside application.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), celebrating its 30th anniversary in 2012, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 17th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sharon Lee
AlphaMed Press
919-680-0011 230
Email >

Marty Murphy, 3rd